Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group trial 9514

Cancer

Volumn 116, Issue 19, 2010, Pages 4613-4621

  Kraybill, William G ^a   Harris, Jonathan ^b   Spiro, Ira J ^c   Ettinger, David S ^d   DeLaney, Thomas F ^c   Blum, Ronald H ^e   Lucas, David R ^f   Harmon, David C ^c   Letson, G Douglas ^g   Eisenberg, Burton ^h  

^a OHIO STATE UNIVERSITY   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e Beth Israel Cancer Center   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^h DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Neoadjuvant chemotherapy; Radiation; Sarcoma

Indexed keywords

DACARBAZINE; DOXORUBICIN; IFOSFAMIDE; MESNA; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; AMPUTATION; ARTHROPATHY; ARTICLE; BLOOD TOXICITY; CARDIOTOXICITY; DIARRHEA; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN TISSUE; INFECTION; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OVERALL SURVIVAL; PAIN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RADIATION DOSE; SKIN TOXICITY; SOFT TISSUE SARCOMA; SUBCUTANEOUS TISSUE; TREATMENT FAILURE; VASCULAR DISEASE; VOMITING; ABDOMINAL WALL; ADJUVANT THERAPY; CLINICAL TRIAL; LIMB; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RISK; SOFT TISSUE NEOPLASMS; THORAX WALL; TREATMENT OUTCOME;

ABDOMINAL WALL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; EXTREMITIES; HUMANS; NEOADJUVANT THERAPY; RADIOTHERAPY, ADJUVANT; RISK; SOFT TISSUE NEOPLASMS; THORACIC WALL; TREATMENT OUTCOME;

EID: 77957574547     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25350     Document Type: Article

References (37)

1. Lawrence WJR, Donegan WL, Natarajan N, et al. A pattern of care survey of the American College of Surgeons. Ann Surg. 1987;205:349-359.
2. Lindberg RD, Martin RG, Romsdahl MM, et al. Conservative surgery and postoperative radiotherapy in 300 adults with soft-tissue sarcomas. Cancer. 1981;47:2392-2397.
3. Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of limb-sparing surgery plus radiation therapy compared with amputation and the role of adjuvant chemotherapy. Ann Surg. 1982;196:305-315.
4. Pisters PW, Harrison LB, Leung DH, et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol. 1996;14:859-868.
5. Rydholm A, Gustafson P, Rooser B, et al. Limb-sparing surgery without radiotherapy based on anatomic location of soft tissue sarcoma. J Clin Oncol. 1991;10:1757-1765.
6. Baldini EH, Goldberg J, Jenner C, et al. Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J Clin Oncol. 1999;17:3252-3259.
7. Stinson SF, DeLaney TF, Greenberg J, et al. Acute and long-term effects on limb function of combined modality limb sparing therapy for extremity soft tissue sarcoma. Int J Radiat Oncol Biol Phys. 1991;221:1493-1499.
8. Delaney TF, Rosenberg D, Harmon DC, et al. Soft tissue sarcomas. In: Price P, Sikora K, eds. Treatment of Cancer. 4th ed. London, UK: Arnold; 2002:867-907.
9. Potter DA, Glenn J, Kinsella T, et al. Patterns of recurrence in patients with high-grade soft-tissue sarcomas. J Clin Oncol. 1985;3:353-366.
10. Kraybill WG, Harris J, Spiro IJ, et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J Clin Oncol. 2006;24:619-625.
11. Spiro IJ, Suit H, Gebhardt M, et al. Neoadjuvant chemotherapy and radiotherapy for large soft tissue sarcomas [abstract]. Proc Am Soc Clin Oncol. 1996;15:524. Abstract 168.
12. DeLaney TF, Spiro IJ, Suit HD, et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Biol Phys. 2003;56:1117-1127.
13. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: Wiley; 1980:163-178.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
15. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) [editorial]. Int J Radiat Oncol Biol Phys. 1995;31:1341-1346.
16. Karakousis CP, Proimakis C, Walsh DL. Primary soft tissue sarcoma of the extremities in adults. Br J Surg. 1995;82:1208-1212.
17. Fabrizio PL, Stafford SL, Pritchard DJ. Extremity soft-tissue sarcomas selectively treated with surgery alone. Int J Radiat Oncol Biol Phys. 2000;48:227-232.
18. Kim B, Chen YL, Goldberg SI, et al. An effective preoperative three-dimensional radiotherapy target volume for extremity soft tissue sarcoma and the effect of margin width on local control. Int J Radiat Biol Phys. 2010;77:843-850.
19. Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998;16:197-203.
20. O'Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomized trial. Lancet. 2002;359:2235-2241.
21. O'Sullivan B, Davis A, Turcotte R, et al. Five-year results of a randomized phase III trial of pre-operative vs post-operative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol. 2004;22:9007.
22. Davis A, O'Sullivan, Turcotte R, et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol. 2005;75:48-53.
23. Coindre JM, Terrier P, Bui NB, et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma: a study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol. 1996;14:869-877.
24. Edmonson JH, Petersen IA, Shives TC, et al. Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas. Cancer. 2002;94:786-792.
25. Nedea EA, Spiro IJ, Suit HD, et al. Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas [abstract]. Int J Radiat Oncol Biol Phys. 2006;66(3 suppl):S118.
26. Bramwell VHC. Controversies in surgical oncology: routine anthracycline-based adjuvant chemotherapy for stage III extremities soft tissue sarcoma. Ann Surg Oncol. 2007;14:1254-1256.
27. Bear HD, Anderson S, Smith RE, et al. A randomized trial comparing preoperative (preop) doxorubicin/cyclophosphamide (AC) to preop AC followed by preop docetaxel (T) and to preop AC followed by postoperative (postop) T in patients (pts) with operable carcinoma of the breast: results of NSABP B-27 [abstract]. Breast Cancer Res Treat. 2005;88:S16. Abstract 26.
28. Goorin AM, Schwartzentruber DJ, Devidas M, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol. 2003;21:1574-1580.
29. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet. 1997;350:1647-1654.
30. Pervaiz N, Cotterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113:573-581.
31. Italiano A, Penel N, Robin YM, et al. Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. Ann Oncol. 2009;20:425-430.
32. Le Cesne A, Van Glabbeke MV, Woll PJ, et al. The end of adjuvant chemotherapy (adCT) era with doxorubicin-based regimen in resected high-grade soft tissue sarcoma (STS): pooled analysis of the two STBSG-EORTC phase III clinical trials [abstract]. J Clin Oncol.26;(suppl):2008. Abstract 10525.
33. Eilber FC, Eilber FR, Eckardt J, et al. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg. 2004;240:686-697.
34. Eilber FC, Brennan MF, Eilber FR, et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg. 2007;246:105-113.
35. Duffaud F, Le Cesne A. Imatinib in the treatment of solid tumors. Target Oncol. 2009;4:45-56.
36. Kolb EA, Gorlick R. Development of IGF-IR inhibitors in pediatric sarcomas. Curr Oncol Rep. 2009;11:307-313.
37. Lopez G, Liu J, Ren W, et al. Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clin Cancer Res. 2009;15:3472-3483.